Sumitomo Chemical India Limited released its unaudited financial results for the quarter and nine months ended 31st December 2025, presenting a mixed performance picture with quarterly challenges offset by strong nine-month growth. The agro-chemicals company's Board of Directors approved these results at a meeting held on 27th January 2026.

Quarterly Performance Shows Decline

The company's standalone performance for Q3FY26 reflected challenging market conditions. Net profit declined by 11.2% year-on-year to ₹748.26 million compared to ₹843.11 million in Q3FY25. Revenue from operations also decreased by 11.4% to ₹5,517.58 million from ₹6,224.29 million in the corresponding quarter of the previous year.

Nine-Month Results Demonstrate Resilience

Despite quarterly headwinds, the nine-month performance showcased the company's underlying strength. For the period ended 31st December 2025, net profit increased by 7.2% to ₹4,325.29 million compared to ₹4,035.41 million in the corresponding nine-month period of FY25. Revenue from operations grew by 3.7% to ₹25,142.71 million from ₹24,255.67 million in the previous year.

Exceptional Items Impact Results

The quarterly results were significantly affected by exceptional items amounting to ₹151.86 million. These charges relate to the implementation of four Labour Codes notified by the Government of India on 21st November 2025, consolidating 29 existing labour laws. The company classified this regulatory-driven impact as exceptional due to its non-recurring nature.

Consolidated Performance Mirrors Standalone Trends

The consolidated results, which include two subsidiary companies, followed similar patterns. Consolidated net profit for Q3FY26 stood at ₹758.00 million compared to ₹874.30 million in Q3FY25, while nine-month consolidated net profit reached ₹4,316.59 million versus ₹4,066.58 million in the previous year. Consolidated revenue for the quarter was ₹5,679.78 million against ₹6,419.19 million in Q3FY25.

Operational and Regulatory Considerations

The company operates exclusively in the agro-chemicals segment, with business performance remaining seasonal and dependent on monsoon and climatic conditions. Sumitomo Chemical continues to monitor ongoing legal proceedings regarding Glyphosate usage restrictions, with petitions filed before the Delhi High Court challenging government notifications from October 2022. The company maintains that these regulations will not be implemented until petition disposal.

The financial results were reviewed by BSR & Co. LLP, Chartered Accountants, and approved by the Audit Committee before Board approval. The company's paid-up equity share capital remains unchanged at ₹4,991.46 million with a face value of ₹10 per share.

Sumitomo Chemical India Limited has announced that its Board of Directors will meet on January 27, 2026, to review the company's third quarter financial performance for fiscal year 2026. The meeting represents a key milestone in the company's quarterly reporting cycle and regulatory compliance obligations.

Board Meeting Details

The scheduled board meeting will comprehensively evaluate the company's financial position through multiple reporting frameworks:

Regulatory Compliance Framework

The announcement demonstrates Sumitomo Chemical India Limited's adherence to established regulatory protocols. The company has fulfilled its disclosure obligations under Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about board meetings scheduled to consider financial results.

Stock Exchange Notifications

Sumitomo Chemical India Limited has formally communicated this board meeting schedule to both major Indian stock exchanges:

Corporate Governance Standards

The timely announcement reflects the company's commitment to maintaining transparent communication with stakeholders and regulatory bodies. By providing advance notice of the board meeting, Sumitomo Chemical India Limited ensures that investors and market participants have adequate information about upcoming financial disclosures. The company's proactive approach to regulatory compliance strengthens investor confidence and supports market transparency initiatives.